Related Experiment Video
Updated: Jul 25, 2025
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Gasdermin D Plays an Oncogenic Role in Glioma and Correlates to an Immunosuppressive Microenvironment
Mengyuan Li1, Ping Jiang1, Shuhua Wei1
1Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China.
Background:
Understanding the molecular mechanisms driving oncogenic processes in glioma is important in order to develop efficient treatments. Recent studies have proposed gasdermin D (GSDMD) as a newly discovered pyroptosis executive protein associated with tumorigenesis. However, the precise effect of GSDMD on glioma progression remains unknown.
Methods:
The expression levels of GSDMD in 931 glioma and 1157 normal control tissues were collected. A series of bioinformatic approaches and in vivo and in vitro experiments were used to investigate the roles and mechanisms of GDSMD in glioma.
Results:
Significant upregulation of GSDMD was detected in glioma tissues compared to normal brain tissues. Patients with glioma and higher GSDMD levels had shorter overall survival, and the Cox regression analysis revealed that GSDMD was an independent risk factor. In addition, upregulation of GSDMD was associated with higher tumor mutation burden and PD-1/PD-L1 expression. Immune infiltration and single-cell analyses indicated that GSDMD was positively associated with an immunosuppressive microenvironment with more infiltrated macrophages and cancer-associated fibroblasts. Furthermore, the in vitro and in vivo experiments revealed that GSDMD knockdown inhibited glioma proliferation, migration, and growth in vivo.
Conclusion:
Our analyses revealed a relatively comprehensive understanding of the oncogenic role of GSDMD in glioma. GSDMD is a promising prognostic biomarker and a potential target for glioma treatment.
Insights
Gasdermin D (GSDMD) is upregulated in glioma, correlating with poorer survival and promoting tumor growth. Targeting GSDMD may offer a new therapeutic strategy for glioma patients.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Glioma pathogenesis involves complex molecular mechanisms.
- Gasdermin D (GSDMD) is implicated in tumorigenesis, but its role in glioma is unclear.
Purpose of the Study:
- To investigate the role and mechanisms of GSDMD in glioma progression.
Main Methods:
- Analysis of GSDMD expression in 931 glioma and 1157 normal tissues.
- Bioinformatic approaches, in vivo, and in vitro experiments were employed.
- Immune infiltration and single-cell analyses were performed.
Main Results:
- GSDMD was significantly upregulated in glioma tissues, associated with shorter survival and acting as an independent risk factor.
- Elevated GSDMD correlated with increased tumor mutation burden, PD-1/PD-L1 expression, and an immunosuppressive microenvironment.
- GSDMD knockdown inhibited glioma proliferation, migration, and in vivo tumor growth.
Conclusions:
- GSDMD plays a significant oncogenic role in glioma.
- GSDMD serves as a potential prognostic biomarker and therapeutic target for glioma.
More Related Videos
Related Concept Videos
02:17The Tumor Microenvironment
02:38Mitogens and the Cell Cycle
01:27Tumor Immunotherapy
02:23Abnormal Proliferation